Compare RANI & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RANI | ROMA |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 133.4M |
| IPO Year | 2021 | 2024 |
| Metric | RANI | ROMA |
|---|---|---|
| Price | $1.40 | $2.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 322.8K |
| Earning Date | 11-06-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,200,000.00 | ★ $1,640,101.00 |
| Revenue This Year | $414.59 | N/A |
| Revenue Next Year | $30.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 59.60 |
| 52 Week Low | $0.39 | $0.58 |
| 52 Week High | $3.87 | $4.66 |
| Indicator | RANI | ROMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 56.15 |
| Support Level | $1.31 | $1.42 |
| Resistance Level | $1.44 | $3.27 |
| Average True Range (ATR) | 0.08 | 0.47 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 43.14 | 56.40 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.